{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Survey Questions

  1. In clinical practice, what are the important factors that influence your decision for therapeutic options in diabetic patients? *

  2. In your practice, which of the following is commonly observed comorbidity in a patient with diabetes? *

  3. In what percentage of your diabetic patients do you see ineffectiveness with metformin monotherapy? *

  4. According to you, what is the most common reason why diabetic patient are on multiple drugs? *

  5. What is the most important factor to consider in dose selection of an anti-diabetic drug? *

  6. How do you choose the best time to prescribe the oral hypoglycemic agent? *

  7. On what basis do you decide to escalate the dose of anti-diabetic drug? *

  8. Do you consider combination therapy as an initial step for intensive glycaemic control? *

  9. Which drug is your first preference for add on therapy if there is a failure with metformin monotherapy? *

  10. Do you find sitagliptin to be effective in controlling post-prandial hyperglycemia in wide range of patients (young and elderly)? *

  11. In your practice, what percentage of patients have cardiovascular or renal comorbidities along with diabetes? *

  12. In patients with long standing diabetes and renal dysfunction, on metformin monotherapy, which of the following drugs do you prefer adding? *

  13. In patients with diabetes and cardiovascular dysfunction, on metformin monotherapy, which of the following class of drugs do you prefer adding? *

  14. Do you prefer initiating combination therapy (intensive glucose lowering therapy) in a young diabetic patient? *

  15. Do you see more complications in young diabetics in recent times? *

  16. Which drug is your first preference for add on therapy in case of compelling need to minimize hypoglycemia? *

  17. Would the availability of Metformin + Glimepiride + Sitagliptin combination help you to switch patients with poor glycemic control from their current therapeutic regimen to this regimen? *

  18. Who would be the ideal candidate for this combination with regards to age? *

  19. Which patient profile would benefit most from this combination? *

  20. Which factors would you consider for prescribing this combination? *

  21. Would cardiovascular benefits be an important factor in the prescription of this combination? *

  22. Would this combination be beneficial in patients with diabetes and CKD? *

  23. What benefits from their respective drug classes do you think will become possible by this combination? *

  24. What do you anticipate about the therapeutic efficacy of this combination? *

  25. How much of an impact would this combination have on weight gain? *

  26. Do you anticipate any safety concerns with this combination? *

  27. What tolerability profile do you expect this combination to have? *

  28. Would there be any hypoglycemia concerns with this combination? *

  29. What metabolic parameters would you monitor for patients who are on this combination? *

  30. What compliance benefits do you foresee with this single-pill combination becoming available? *

  31. Which patients with adequate glycaemic control would still be considered for early implementation of this combination therapy? *

  32. Would comorbidities and risk factors like hypertension, dyslipidemia, smoking, alcohol consumption or sedentary lifestyle play a role in prescribing this combination? *

  33. Would you consider this combination as initial triple therapy in newly diagnosed patients? *

  34. How do you think will a cost-benefit analysis work out for most of your patients who would be prescribed this combination? *